Nipradilol (BioDeep_00000181687)

   

human metabolite blood metabolite


代谢物信息卡片


8-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}-3,4-dihydro-2H-1-benzopyran-3-yl nitrate

化学式: C15H22N2O6 (326.1477792)
中文名称: 尼普地洛
谱图信息: 最多检出来源 Homo sapiens(blood) 66.67%

分子结构信息

SMILES: CC(C)NCC(COC1=CC=CC2=C1OCC(C2)O[N+](=O)[O-])O
InChI: InChI=1S/C15H22N2O6/c1-10(2)16-7-12(18)8-21-14-5-3-4-11-6-13(23-17(19)20)9-22-15(11)14/h3-5,10,12-13,16,18H,6-9H2,1-2H3

描述信息

C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

同义名列表

4 个代谢物同义名

8-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}-3,4-dihydro-2H-1-benzopyran-3-yl nitrate; 3,4-Dihydro-8-(2-hydroxy-3--isopropylaminopropoxy)-3-nitroxy-2H-1-benzopyran; Nipradilol; Hypadil



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Yasuko Tatsumi, Akiyasu Kanamori, Azusa Nagai-Kusuhara, Yoriko Nakanishi, Neeraj Agarwal, Akira Negi, Makoto Nakamura. Nipradilol protects rat retinal ganglion cells from apoptosis induced by serum deprivation in vitro and by diabetes in vivo. Current eye research. 2008 Aug; 33(8):683-92. doi: 10.1080/02713680802323157. [PMID: 18696344]
  • Azusa Nagai-Kusuhara, Makoto Nakamura, Hirokazu Mukuno, Akiyasu Kanamori, Akira Negi, Gail M Seigel. cAMP-responsive element binding protein mediates a cGMP/protein kinase G-dependent anti-apoptotic signal induced by nitric oxide in retinal neuro-glial progenitor cells. Experimental eye research. 2007 Jan; 84(1):152-62. doi: 10.1016/j.exer.2006.09.010. [PMID: 17081519]
  • Ikuko Kimura. Medical benefits of using natural compounds and their derivatives having multiple pharmacological actions. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 2006 Mar; 126(3):133-43. doi: 10.1248/yakushi.126.133. [PMID: 16508237]
  • Akira Ando, Yukari Yamazaki, Shiho Kaneko, Maki Miyake, Rie Nambu, Makoto Taomoto, Sawako Unezaki, Emiko Okuda-Ashitaka, Tadayoshi Okumura, Seiji Ito, Miyo Matsumura. Cytoprotection by nipradilol, an anti-glaucomatous agent, via down-regulation of apoptosis related gene expression and activation of NF-kappaB. Experimental eye research. 2005 Apr; 80(4):501-7. doi: 10.1016/j.exer.2004.10.014. [PMID: 15781277]
  • Yoshihiro Suematsu, Vesa Anttila, Shinichi Takamoto, Pedro del Nido. Cardioprotection afforded by ischemic preconditioning interferes with chronic beta-blocker treatment. Scandinavian cardiovascular journal : SCJ. 2004 Oct; 38(5):293-9. doi: 10.1080/14017430410021507. [PMID: 15513313]
  • Masahiko Igarashi, Akihiko Hirata, Hiroshi Yamaguchi, Naoko Sugae, Yuko Kadomoto, Yumi Jimbu, Makoto Daimon, Takeo Kato, Makoto Tominaga. Mechanism of an inhibitory effect of nipradilol on rat vascular smooth muscle cell growth. Journal of atherosclerosis and thrombosis. 2003; 10(4):226-33. doi: 10.5551/jat.10.226. [PMID: 14566085]
  • Yoshihiro Takamitsu, Takeshi Nakanishi, Futoshi Nishihara, Yukiko Hasuike, Masaaki Izumi, Toru Inoue, Keisuke Hiraoka, Reiko Itahana, Koji Miyagawa. A nitric oxide-generating beta-blocking agent prevents renal injury in the rat remnant kidney model. Comparative study of two beta-blocking drugs, nipradilol and propranolol. Nephron. Physiology. 2003; 93(2):p42-50. doi: 10.1159/000068529. [PMID: 12629270]
  • Hiroshi Tomita, Toru Nakazawa, Eriko Sugano, Toshiaki Abe, Makoto Tamai. Nipradilol inhibits apoptosis by preventing the activation of caspase-3 via S-nitrosylation and the cGMP-dependent pathway. European journal of pharmacology. 2002 Oct; 452(3):263-8. doi: 10.1016/s0014-2999(02)02329-4. [PMID: 12359266]
  • Kenji Kashiwagi, Yoko Iizuka, Shigeo Tsukahara. Neuroprotective effects of nipradilol on purified cultured retinal ganglion cells. Journal of glaucoma. 2002 Jun; 11(3):231-8. doi: 10.1097/00061198-200206000-00012. [PMID: 12140401]
  • Navin Kumar Thakur, Toshio Hayashi, Daigo Sumi, Hatsuyo Kano, Hisako Matsui-Hirai, Taku Tsunekawa, Akihisa Iguchi. Anti-atherosclerotic effect of beta-blocker with nitric oxide-releasing action on the severe atherosclerosis. Journal of cardiovascular pharmacology. 2002 Feb; 39(2):298-309. doi: 10.1097/00005344-200202000-00017. [PMID: 11791016]
  • Yoshihiro Suematsu, Toshiya Ohtsuka, Hitoshi Horimoto, Katsuhide Maeda, Yasunari Nakai, Shigetoshi Mieno, Shinichi Takamoto. Long-term treatment with nipradilol, a nitric oxide-releasing beta-adrenergic blocker, enhances postischemic recovery and limits infarct size. The Annals of thoracic surgery. 2002 Jan; 73(1):173-9. doi: 10.1016/s0003-4975(01)03234-9. [PMID: 11834008]
  • Y Otsuka, S Harasawa, H Sugiura, M Koike, H Akimoto, T Ishii, H Abeta, T Okabe, T Kushiro, K Kanmatsuse. [The effect of exogenous nitric oxide on endothelial dysfunction in two-kidney, one-clip renovascular hypertensive rats]. Nihon Jinzo Gakkai shi. 2000 Oct; 42(8):619-24. doi: NULL. [PMID: 11195397]
  • I Kosegawa, M Inaba, T Morita, T Awata, S Katayama. Effect of the vasodilatory beta-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension. Clinical and experimental hypertension (New York, N.Y. : 1993). 1998 Oct; 20(7):751-61. doi: 10.3109/10641969809052117. [PMID: 9764719]
  • K Nitta, T Tsutsui, K Uchida, Y Eto, K Natori, K Honda, W Yumura, H Nihei. Nipradilol inhibits DNA synthesis by regulating nitric oxide synthesis in cultured rat mesangial cells. European journal of pharmacology. 1998 Feb; 344(1):107-10. doi: 10.1016/s0014-2999(97)01613-0. [PMID: 9570455]
  • T Hayashi, K Yamada, T Esaki, E Muto, A Iguchi. The beta adrenoreceptor antagonist, nipradilol, preserves the endothelial nitric oxide response in atherosclerotic vessels of rabbit. Life sciences. 1997; 61(14):1379-87. doi: 10.1016/s0024-3205(97)00683-8. [PMID: 9335227]
  • B Takase, A Kurita, A Uehata, H Hikita, T Nishioka, H Mitani, K Satomura, K Mizuno, H Nakamura. Effect of nipradilol on silent myocardial ischemia, plasma beta-endorphin, and bradykinin in chronic stable angina. Clinical cardiology. 1996 Jun; 19(6):477-82. doi: 10.1002/clc.4960190607. [PMID: 8790952]
  • T Yoshikawa, S Handa, M Akaishi, H Mitamura, S Ogawa. Effect of a new beta-blocker, nipradilol, on cardiac function and neurohumoral factors in idiopathic dilated cardiomyopathy. Japanese circulation journal. 1996 May; 60(5):285-92. doi: 10.1253/jcj.60.285. [PMID: 8803722]
  • T Yoshikawa, S Handa, T Anzai, H Nishimura, A Baba, M Akaishi, H Mitamura, S Ogawa. Early reduction of neurohumoral factors plays a key role in mediating the efficacy of beta-blocker therapy for congestive heart failure. American heart journal. 1996 Feb; 131(2):329-36. doi: 10.1016/s0002-8703(96)90362-2. [PMID: 8579029]
  • T Adachi, S Hori, K Miyazaki, E Takahashi, M Nakagawa, A Udagawa, N Hayashi, N Aikawa, S Ogawa. Rapid increase in plasma nitrite concentration following intravenous administration of nipradilol. European journal of pharmacology. 1995 Nov; 286(2):201-4. doi: 10.1016/0014-2999(95)00559-4. [PMID: 8605957]
  • A Naito, Y Aniya, M Sakanashi. Antioxidative action of the nitrovasodilator nicorandil: inhibition of oxidative activation of liver microsomal glutathione S-transferase and lipid peroxidation. Japanese journal of pharmacology. 1994 Jul; 65(3):209-13. doi: 10.1254/jjp.65.209. [PMID: 7799521]
  • D Koya, R Kikkawa, M Haneda, T Uzu, M Sawada, N Kajiwara, K Sakamoto, T Sugimoto, Y Shigeta. Nipradilol inhibits rat mesangial cell mitogenesis through the activation of soluble guanylate cyclase. European journal of pharmacology. 1993 Mar; 245(1):79-82. doi: 10.1016/0922-4106(93)90173-7. [PMID: 8097473]
  • H Kishida, T Saito, J Nejima, N Hata, Y Kusama, T Suzuki, F Otsu, H Kaneko, N Inokuchi. Evaluation of a new antianginal agent, nipradilol, in effort angina using holter monitoring. Japanese heart journal. 1988 May; 29(3):309-17. doi: 10.1536/ihj.29.309. [PMID: 2902238]
  • H Hisa, M Suzuki-Kusaba, S Satoh. Effects of K-351 on adrenergically induced renin release and renal vasoconstriction in anesthetized dogs. Journal of cardiovascular pharmacology. 1987 Jan; 9(1):1-5. doi: 10.1097/00005344-198701000-00001. [PMID: 2434783]
  • M Yoshimura, J Kojima, T Ito, J Suzuki. Pharmacokinetics of nipradilol (K-351), a new antihypertensive agent. I. Studies on interspecies variation in laboratory animals. Journal of pharmacobio-dynamics. 1985 Sep; 8(9):738-50. doi: 10.1248/bpb1978.8.738. [PMID: 4087134]
  • M Yoshimura, J Kojima, T Ito, J Suzuki. Structural determination of dog and human urinary metabolites of nipradilol (K-351), a new antihypertensive agent. Chemical & pharmaceutical bulletin. 1985 Aug; 33(8):3456-68. doi: 10.1248/cpb.33.3456. [PMID: 2867833]
  • T X Watanabe, H Sokabe, K Kawashima. An analysis of blood pressure effects of nipradilol and prizidilol in normotensive and spontaneously hypertensive rats. Japanese journal of pharmacology. 1985 Jul; 38(3):273-9. doi: 10.1254/jjp.38.273. [PMID: 3903298]
  • M Yoshimura, J Kojima, T Ito, M Fujii, J Suzuki. Pharmacokinetics of nipradilol (K-351), a new antihypertensive agent. II. Influence of the route of administration on bioavailability in dogs. Journal of pharmacobio-dynamics. 1985 Jul; 8(7):503-12. doi: 10.1248/bpb1978.8.503. [PMID: 4067813]
  • S Kabuto, H Kimata, M Yonemitsu, T Koide, H Nakao, J Suzuki. Pharmacokinetics of the new antihypertensive agent nipradilol in rats. 1st communication: Metabolism and disposition after single oral administration of [14C]nipradilol. Arzneimittel-Forschung. 1985; 35(11):1674-9. doi: NULL. [PMID: 3937533]
  • H Kimata, S Kabuto, M Yonemitsu, T Koide, H Nakao, J Suzuki. Pharmacokinetics of the new antihypertensive agent nipradilol in rats. 2nd communication: A single oral administration of [14C]nipradilol to spontaneously hypertensive rats. Arzneimittel-Forschung. 1985; 35(11):1680-4. doi: NULL. [PMID: 4091870]
  • K Kawashima, T X Watanabe, H Sokabe. Pharmacodynamic and pharmacokinetic studies on prizidilol and nipradilol (K-351), antihypertensive drugs with combined vasodilator and beta-adrenoceptor blocking actions, in rabbits. Japanese journal of pharmacology. 1984 Dec; 36(4):519-26. doi: 10.1254/jjp.36.519. [PMID: 6151998]
  • H Hisa, M Suzuki, T Kamijo, S Satoh. Effects of K-351 on hemodynamics and renin release in anesthetized dogs. Archives internationales de pharmacodynamie et de therapie. 1984 Sep; 271(1):169-76. doi: NULL. [PMID: 6149735]
  • L Giuliani, G Carmignani, E Belgrano, P Puppo. Transcatheter arterial embolization in urological tumors: the use of isobutyl-2-cyanoacrylate. The Journal of urology. 1979 May; 121(5):630-4. doi: 10.1016/s0022-5347(17)56913-x. [PMID: 439260]
  • A W Mondorf. [Evidence of urinary tubular proteins in inflammatory and toxic kidney damage]. Wiener medizinische Wochenschrift. Supplement. 1975; 27(?):20-3. doi: NULL. [PMID: 5816]